Sera Prognostics’ PreTRM® Named Edison Awards F

SALT LAKE CITY, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, a women’s heath company, today announced that PreTRM®, the first and only clinically-validated blood test that provides an early and individualized prediction of preterm birth risk, has been named a 2017 Award Finalist by the internationally renowned Edison Awards™.   These distinguished awards, inspired by Thomas Edison’s persistence and inventiveness, recognize leadership in innovation, creativity and ingenuity in the global economy.

“It’s exciting to see companies like Sera Prognostics continuing Thomas Edison’s legacy of challenging conventional thinking,” said Frank Bonafilia, Edison Awards’ executive director.  “Edison Awards recognizes the game-changing products and services, and the teams that brought them to consumers.” Award winners will be announced April 20, 2017 at the Edison Awards Annual Gala, held in the historic Ballroom of the Capitale in New York City.

“We are honored to have been selected by the prestigious awards committee from hundreds of submissions as a finalist for Sera’s innovative PreTRM blood test,” said Gregory C. Critchfield, M.D., M.S., chairman and chief executive officer of Sera Prognostics. “The Edison Awards celebrate innovations that have a meaningful impact around the world.  Sera’s goal of improving neonatal health and healthcare economics in the U.S. and worldwide is congruent with the Edison Awards mission.  Through our PreTRM test, we are working to reduce the social and economic burden of prematurity by providing both physicians and patients the opportunity to intervene earlier, with the goal of improving the lives of women and their babies.”

Edison Awards nominees are judged by more than 3,000 senior business executives and academics from across the nation whose votes acknowledge the Finalists’ success in meeting the award’s stringent criteria of quality.  The voting panel includes members of:

Chief Marketing Officer Council (CMO) Design Management Institute (DMI) American Productivity & Quality Center (APQC) American Society of Mechanical Engineers (ASME) Georgia State Marketing Roundtable (GSU) Product Development and Management Association (PDMA)   Assoc. of Technology Mgmt & Applied Engineering (ATMAE) BPI Network Past Edison Award winners Marketing professionals Scientists Designers Engineers   Academics

About the PreTRM ^® Test

The PreTRM ^® test is the first and only clinically validated blood test that provides an early and individual risk prediction for spontaneous preterm birth in asymptomatic, singleton pregnancies. The PreTRM® test measures and analyzes proteins in the blood that are highly predictive of preterm birth.  The PreTRM® test can help physicians identify early in the pregnancy (as early as 19 weeks of gestation) which women are at increased risk for premature delivery, enabling more informed clinical decisions based on each woman’s individual risk. The PreTRM® test enables researchers to better understand the causes of preterm birth and to develop new therapies to improve newborn health.

The PreTRM® test is ordered by a medical professional.

For more information about the PreTRM test, please visit www.PreTRM.com and the PreTRM® test YouTube Channel.  You can also join the conversation on Facebook and @PreTRM.

About Sera Prognostics, Inc.

Sera Prognostics, a women’s health company, develops innovative diagnostic tests focused on the early prediction of preterm birth (PTB) risk and other complications of pregnancy. Sera has launched its PreTRM ^® test, the first and only clinically validated blood test to accurately predict early in pregnancy the risk of premature birth. The test objectively reports to the physician the risk of premature delivery, enabling earlier proactive interventions designed to prolong gestation and improve neonatal health outcomes. Sera’s technology addresses both the health and economic challenges of PTB. The Company’s strong management team has significant clinical development and women's healthcare diagnostic experience. Sera is backed by highly respected healthcare investors, including Domain Associates, InterWest Partners, Catalyst Health Ventures, the Bill & Melinda Gates Foundation, and LabCorp, who recently entered into an agreement with the Company to become the exclusive US distributor of the PreTRM® test. Currently, Sera is working with the Gates Foundation to translate the Company’s discoveries into technologies well suited for low-income countries in its journey to improve maternal and infant health globally. Sera Prognostics is located in Salt Lake City, Utah. For more information, please visit the company's website at www.seraprognostics.com . 

The Edison Awards is a program conducted by Edison Universe, a 501(c)(3) charitable organization dedicated to fostering  future innovators.   For more information about the Edison Awards, Edison Universe and a list of past winners, visit www.edisonawards.com .

Company Contact: Andrew Sauter, CFO Sera Prognostics, Inc. info@seraprognostics.com (801) 990-0772 Media Contact for Sera Prognostics: Terri Clevenger Continuum Health Communications tclevenger@continuumhealthcom.com (203) 856-4326